[1] Kuliszkiewicz-Janus, M. and Baczyński, S. Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myleoma. NMR Biomed. 8 (1995) 127–132. http://dx.doi.org/10.1002/nbm.1940080308CrossrefGoogle Scholar

[2] Kuliszkiewicz-Janus, M. and Baczyński, S. Application of 31P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas. Magn. Reson. Med. 35 (1996) 449–456. CrossrefGoogle Scholar

[3] Kuliszkiewicz-Janus, M. and Baczyński, S. Treatment induces changes in 31P MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia. Biochim. Biophys. Acta 1360 (1997) 71–83. Google Scholar

[4] Kuliszkiewicz-Janus, M., Janus, W. and Baczyński, S. Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res. 16 (1996) 1587–1594. Google Scholar

[5] Kuliszkiewicz-Janus, M., Janus, W., Baczyński, S. and Jurczyk, A. Bone marrow transplantation In the course of hematological malignancies- fellow up to study in blond serum by 31P NMR. Med. Sci. Monit. 10 (2004) 485–492. Google Scholar

[6] Kuliszkiewicz-Janus, M., Tuz, M.A. and Baczyński, S. Application of 31P NMR to the analysis of phospholipids changes in plasma of patients with acute leukemia. Biochim. Biophys. Acta 1737 (2005) 11–15. Google Scholar

[7] Kuliszkiewicz-Janus, M. and Baczyński, S. Phospholipids’ sera and mononuclear cells in acute leukemia, malignant lymphoma and multiple myeloma - evaluation by 31P MRS in vitro. NATO Science Series. II: Mathematics, Physics and Chemistry 76 (2002) 347–354. Google Scholar

[8] Tuz, M.A., Kuliszkiewicz-Janus, M. and Baczyński, S. Application of 31P NMR magnetic resonance spectroscopy to observation of phospholipids concentration changes in blood serum, plasma, peripheral blood mononuclear cells and bone marrow mononuclear cell from patients with hematological cancers - a methodological review. Polish J. Chem. 80 (2006) 1009–1019. Google Scholar

[9] Kuliszkiewicz-Janus, M., Tuz, M.A., Kiełbiński, M., Baczyński, S., Jaźwiec, B. and Śladowska, H. Platelet-activating factor changes In phospholipid extracts from plasma, peripheral blood mononuclear cells and bone marrow mononuclear cell of patients with acute leukemia - A 31P NMR in vitro study. Cell. Mol. Biol. Lett. 13 (2008) 58–66. http://dx.doi.org/10.2478/s11658-007-0035-9Web of ScienceCrossrefGoogle Scholar

[10] Kuliszkiewicz-Janus, M., Tuz, M.A., Baczyński, S., Prajs, I. and Jaźwiec, B. 31P NMR analysis of the phospholipid composition of mormal human peripheral blond mononuclear cells (PBMC). Cell. Mol. Biol. Lett. 10 (2005) 373–382. Google Scholar

[11] Merchant, T.E, de Graaf, P.W., Minsky, B.D., Obertop, H. and Glonek, T. Esophageal cancer phospholipid characterization by 31P NMR. NMR Biomed. 6 (1993) 187–193. http://dx.doi.org/10.1002/nbm.1940060304CrossrefGoogle Scholar

[12] Merchant, T.E., Minsky, B.D., Lauwers, G.Y., Diamantis, P.M., Haida, T. and Glonek, T. Esophageal cancer phospholipids correlated with histopathologic findings: A 31P NMR study. NMR Biomed. 12 (1999) 184–188. http://dx.doi.org/10.1002/(SICI)1099-1492(199906)12:4<184::AID-NBM560>3.0.CO;2-MCrossrefGoogle Scholar

[13] van Blitterswijk, W.J., van der Luit, A.H., Veldman, R.J., Verheij, M. and Borst, J. Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem. J. 369 (2003) 199–211. http://dx.doi.org/10.1042/BJ20021528CrossrefGoogle Scholar

[14] Tepper, A.D., Ruurs, P., Wiedmer, T., Sims, P.J., Borst, J. and van Blitterswijk, W.J. Sphingomyelin hydrolysis to ceramide during the execution phase of apoptosis results from phospholipids scrambling and alters cell-surface morphology. J. Cell Biol. 150 (2000) 155–164. http://dx.doi.org/10.1083/jcb.150.1.155CrossrefGoogle Scholar

[15] Bevers, EM., Comfurius, P., Dekkers, D.W. and Zwaal, R.F. Lipid translocation across the plasma membrane of mammalian cells. Biochim. Biophys. Acta 1439 (1999) 317–330. Google Scholar

[16] Verhoven, B., Schlegel, R.A. and Williamson, P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lyphocytes. J. Exp. Med. 182 (1995) 1597–1601. http://dx.doi.org/10.1084/jem.182.5.1597CrossrefGoogle Scholar

[17] Martin, S.J., Reutelingsperger, C.P., McGahon, A.J., Rader, J.A., van Schie, R.C., LaFace, D.M. and Green, D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182 (1995) 1545–1556. http://dx.doi.org/10.1084/jem.182.5.1545CrossrefGoogle Scholar

[18] Fadok, V.A., Voelker, D.R., Campbell, P.A., Cohen, J.J., Bratton, D.L. and Henson, P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148 (1992) 2207–2216. Google Scholar

[19] Kagan, V.E., Fabisiak, J.P., Shvedova, A.A., Tyurina, Y.Y., Tyurin, V.A., Schor, N.F. and Kawai, K. Oxidative signaling pathway for externalization of plasma membrane phosphatidylserine during apoptosis. FEBS Lett. 477 (2000) 1–7. http://dx.doi.org/10.1016/S0014-5793(00)01707-5CrossrefGoogle Scholar

[20] McConkey, D.J., Zhitovsky, B. and Orrenius, S. Apoptosis — molecular mechanisms and biomedical implications. Mol. Aspects Med. 17 (1996) 1–110. http://dx.doi.org/10.1016/0098-2997(95)00006-2CrossrefGoogle Scholar

[21] Eberhardt, C., Gray, P.W. and Tjoelker, L.W. Human lysophosphatidic acid acytylotransferase. CDNA clonning, expression, and localization to chromosome 9q34.3. J. Biol. Chem. 272 (1997) 20299–20305. http://dx.doi.org/10.1074/jbc.272.32.20299CrossrefGoogle Scholar

[22] Niesporek, S., Denkert, C., Weichert, W., Kobel, M., Noske, A., Sehouli, J., Singer, J.W., Dietel, M. and Hauptmann, S. Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis. Br. J. Cancer 92 (2005) 1729–1736. http://dx.doi.org/10.1038/sj.bjc.6602528CrossrefGoogle Scholar

[23] Springett, G.M., Bonham, L., Hummer, A., Linkov, I., Misra, D., Ma, C., Pezzoni, G., Di Giovine, S., Singer, J., Kawasaki, H., Spriggs, D., Soslow, R. and Dupont, J. Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res. 65 (2005) 9415–9425. http://dx.doi.org/10.1158/0008-5472.CAN-05-0516CrossrefGoogle Scholar

[24] Douvas, M.G., Hogan, K.N., Ji, Y., Hollenback, D., Bonham, L., Singer, J.W. and Mitchell, B.S. Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leuk. Res. 30 (2006) 1027–1036. http://dx.doi.org/10.1016/j.leukres.2005.11.018CrossrefGoogle Scholar

[25] Ruiz-Cabello, J. and Cohen, J.S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 5 (1992) 226–233. CrossrefGoogle Scholar

[26] Gerhard, A., Häfer, R. and Zintl, F. Fatty acid composition of lymphocyte membrane phospholipids in children with acute leukaemia. Cancer Lett. 173 (2001) 139–144. http://dx.doi.org/10.1016/S0304-3835(01)00674-7CrossrefGoogle Scholar

[27] Lin, W.C., Manshouri, T., Jilani, I., Neuberg, D., Patel, K., Kantarjian, H., Andreeff, M., Estrov, Z., Beran, M., Keating, M., Estey, E. and Albitar, M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk. Res. 26 (2002) 551–559. http://dx.doi.org/10.1016/S0145-2126(01)00170-9CrossrefGoogle Scholar

[28] Shuler, D. and Szende, B. Apoptosis in acute leukaemia. Leuk. Res. 28 (2004) 661–666. http://dx.doi.org/10.1016/j.leukres.2003.10.032CrossrefGoogle Scholar

[29] Invernizzi, R., Pecci, A., Bellotti, L. and Ascari, E. Expression of p53, Bcl-2 and Ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk. Lymphoma 42 (2001) 481–489. http://dx.doi.org/10.3109/10428190109064605Google Scholar